484 related articles for article (PubMed ID: 18574390)
1. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
[TBL] [Abstract][Full Text] [Related]
2. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A
Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
[TBL] [Abstract][Full Text] [Related]
4. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.
Marazzi G; Wajngarten M; Vitale C; Patrizi R; Pelliccia F; Gebara O; Pierri H; Ramires JA; Volterrani M; Fini M; Rosano GM
Int J Cardiol; 2007 Aug; 120(1):79-84. PubMed ID: 17134770
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
[TBL] [Abstract][Full Text] [Related]
6. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study.
El-Kady T; El-Sabban K; Gabaly M; Sabry A; Abdel-Hady S
Am J Cardiovasc Drugs; 2005; 5(4):271-8. PubMed ID: 15984909
[TBL] [Abstract][Full Text] [Related]
7. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
8. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM
Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696
[TBL] [Abstract][Full Text] [Related]
9. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
[TBL] [Abstract][Full Text] [Related]
10. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
Sisakian AS; Torgomian AL; Barkhudarian AL
Klin Med (Mosk); 2006; 84(10):55-8. PubMed ID: 17201276
[TBL] [Abstract][Full Text] [Related]
11. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
[TBL] [Abstract][Full Text] [Related]
12. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.
Rosano GM; Vitale C; Sposato B; Mercuro G; Fini M
Cardiovasc Diabetol; 2003 Nov; 2():16. PubMed ID: 14641923
[TBL] [Abstract][Full Text] [Related]
13. Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia.
Ikizler M; Dernek S; Sevin B; Kural T
Anadolu Kardiyol Derg; 2003 Dec; 3(4):303-8. PubMed ID: 14675878
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
[TBL] [Abstract][Full Text] [Related]
15. The acute administration of trimetazidine modified myocardial perfusion and left ventricular function in 31 patients with ischaemic ventricular dysfunction.
Feola M; Biggi A; Francini A; Leonardi G; Ribichini F; Ferrero V; Uslenghi E
Int J Cardiovasc Imaging; 2004 Aug; 20(4):315-20. PubMed ID: 15529915
[TBL] [Abstract][Full Text] [Related]
16. Effects of trimetazidine, a partial inhibitor of fatty acid oxidation, on ventricular function and survival after myocardial infarction and reperfusion in the rat.
Mouquet F; Rousseau D; Domergue-Dupont V; Grynberg A; Liao R
Fundam Clin Pharmacol; 2010 Aug; 24(4):469-76. PubMed ID: 20030737
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefits of a metabolic approach in the cardiac rehabilitation of patients with coronary artery disease.
Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
Am J Cardiol; 2006 Sep; 98(5A):25J-33J. PubMed ID: 16931203
[TBL] [Abstract][Full Text] [Related]
18. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
Onay-Besikci A; Guner S; Arioglu E; Ozakca I; Ozcelikay AT; Altan VM
Can J Physiol Pharmacol; 2007 May; 85(5):527-35. PubMed ID: 17632588
[TBL] [Abstract][Full Text] [Related]
19. Role of trimetazidine in management of ischemic cardiomyopathy.
Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
[TBL] [Abstract][Full Text] [Related]
20. The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow.
Topal E; Ozdemir R; Barutcu I; Aksoy Y; Sincer I; Akturk E; Cehreli S
J Electrocardiol; 2006 Apr; 39(2):211-8. PubMed ID: 16580422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
